Summary Residual retroperitoneal masses may remain after chemotherapy for metastatic non-seminomatous testicular cancer, which harbour residual tumour or totally benign tissue (necrosis/fibrosis). These residual masses may be effectively removed by a surgical resection. We evaluated current selection criteria and tried to develop alternative criteria in a data set of 544 patients, who had retroperitoneal lymph node dissection of residual masses. Six resection policies were identified from the literature. Two alternative policies were developed with logistic regression analysis. Evaluation of the policies focused on the true-positive rate (resection in case of tumour), and the false-positive rate (resection in case of necrosis). It appea'red that most current policies use the size of the residual mass () 10 mm or > 20 mm) as the predominant selection criterion. This resulted in high true-positive rates (most >90%), but false-positive rates between 37% and 87%. The alternative policies included five well-known predictors of necrosis in addition to residual mass size (primary tumour histology, prechemotherapy levels of the three tumour markers alphafetoprotein (AFP), human chorionic gonadotropin (HCG) and lactate dehydrogenase (LDH) and mass shrinkage during chemotherapy). This strategy resulted in improved true-and false-positive rates, even when categories of the predictors were simplified for practical application. We conclude that a simple statistical model, based on a limited number of patient characteristics, provides better guidelines for patient selection than those currently used in clinical practice.
Testicular cancer is the most common malignancy among men in the age between 20 and 35 years. Fortunately, even metastatic disease can currently be cured in the majority (60-80%) of patients with non-seminomatous germ cell tumour, since the introduction of cisplatin-based chemotherapy (Peckham, 1988; Einhorn, 1990) . After chemotherapy, surgical resection is a generally accepted treatment to remove residual retroperitoneal lymph node masses, since these masses still harbour residual tumour in about half of the patients. Alternatively, patients may be treated conservatively, which includes follow-up with regular blood tests and computerised tomography (CT) scans of the abdomen. A uniform approach to the selection of patients for resection is lacking (Toner et al., 1990; Fossa et al., 1992; Hendry et al., 1993; Mulders et al., 1990; Steyerberg et al., 1993) , and percentages of surgically treated patients vary between 20% (Mead et al., 1992; Tait et al., 1984) and 86% (Aass et al., 1991) . Therefore, several large cancer centres cooperated to evaluate the selection criteria for resection.
Resection of residual masses provides the histological diagnosis, which may be purely benign with necrotic and/or fibrotic remnants only (necrosis), or residual tumour (mature teratoma or undifferentiated cancer). In the case of cancer, two additional courses of chemotherapy are usually recommended (Einhorn et al., 1981; Fox et al., 1993) . Although not proven, it may be assumed that this additional therapy reduces the risk of relapse, in addition to the resection itself. Resection of mature teratoma prevents growth of the residual mass (Logothetis et al., 1982) . In contrast, resection of benign masses has no therapeutic benefit. An ideal resection policy would, therefore, result in surgical removal of all masses with residual tumour (mature teratoma or cancer) and in a conservative treatment of all masses with necrosis.
Current selection policies were evaluated in an international data set from six study groups. A statistical model was developed from this same data set, using several well-known predictors of the histology of residual masses (Tait et al., 1984; Donohue et al., 1987; Gelderman et al., 1988; Harding et al., 1989; Toner et al., 1990; Mulders et al., 1990; Steyerberg et al., 1994; Gerl et al., 1995) . Easy-touse alternative selection criteria were based on this analysis and compared with the current policies.
Patients and methods Patients
An international data set was collected, consisting of patients with metastatic non-seminomatous testicular cancer, including patients with pure seminoma and elevated levels of prechemotherapy tumour markers, who underwent resection of retroperitoneal residual masses after induction chemotherapy with cisplatin-based chemotherapy (Steyerberg et al., 1995) . Excluded were patients with elevated tumour markers [alphafetoprotein (AFP) (Harrell et al., 1982) . True-and false-positive rates were calculated with increasing cut-off values for the probability of necrosis.
Comparison of policies
The diagnostic quality of the policies could be compared with the area under the ROC curve, with larger areas indicating better policies. A limitation of the area under the ROC curve is, however, that it does not consider the frequency of the outcome (necrosis/tumour at resection), nor the relative importance of misclassifications (Hilden, 1991) . We, therefore, calculated a weighted classification error. The relative importance (or weight) of missing residual tumour was set as 1, 2, 4, 8 and 16 times that of unnecesary action. The weighted classification error was expressed as the number of unnecessary resections of necrosis and was calculated as: (number of unnecessary resections) + (weight x number of missed resections of tumour).
McNemar's test for paired observations was used for statistical comparisons between the policies (McNemar, 1947) . Since the test assumes equal weights for false-positive and false-negative misclassifications, fair statistical comparisons could only be made if one policy dominated, i.e. had both a higher true-and a lower false-positive rate.
Verification bias
In this analysis, data are only available from patients where the residual histology was verified by resection. These patients were selected from the total population of patients with normal tumour markers after chemotherapy according to the centre-specific selection policies. These policies had resulted in an average of 31% of the resections being performed in masses with a size of 0-10 mm (Steyerberg et al., 1995) . This selection may have led to a bias, labelled verification bias (Ransohoff and Feinstein, 1978; Begg and Greenes, 1983) . This bias would lead to overestimated trueand false-positive rates, but to largely unbiased predicted probabilities of necrosis. Correction for verification bias in the international data set is difficult, since six different centres participated. Fortunately, in one centre resection was performed routinely (NRH, n = 127) (Aass et al., 1991) , such that virtual absence of verification bias might be assumed here. This assumption was supported by the observation that 43% of the NRH resections had been performed in masses with a size of 0 -10 mm. The policies were, therefore, also evaluated separately in these 127 patients.
Results Table I shows the current resection policies that were evaluated. The histological distribution is shown in masses that would be resected or treated conservatively according to each policy. Table I that the probability of necrosis was 38% in masses > 10 mm, in contrast to 72% in masses < 10 mm. The second policy (resection of masses >20 mm) has been used especially in British centres (Tait et al., 1984; Mead et al., 1992; Hendry et al., 1993) . It would leave masses unresected with a low risk of undifferentiated cancer (4%), but a considerable risk of mature teratoma (30%). Policies 3 to 5 use one or more patient characteristics in addition to residual mass size. If resection is performed in all patients with a teratoma-positive tumour (policy 3, Gelderman et al., 1988) , the risk of leaving tumour unresected reduces to 23% (15%+8%) compared with 28% with policy 1. Policy 4 (Toner et al., 1990) leads to similar risk of missing residual tumour compared with policy 1 (30% vs 28%). Policy 5 consists of resection in all patients, except a small subgroup with residual masses <20 mm and three favourable characteristics (primary tumour teratoma-negative and prechemotherapy AFP and HCG normal). This stringent practice does not guarantee that no tumour is missed, but the risk is low (6% + 6% = 12%). Policy 6 (Donohue et al., 1987) consists of conservative treatment of patients with a shrinkage over 70% and a teratoma-negative primary tumour. Residual tumour was found in 24% (17% + 7%) of these patients.
Alternative resection policies Alternative resection policies were based on statistical analysis of the international data set. The results of an analysis with continuous predictors are presented in Table II (Steyerberg et al., 1995) . The probability of necrosis corresponds to the sum score and can readily be calculated for individual patients. Exact formulas to calculate the probability of necrosis, mature teratoma and cancer are presented in the Appendix.
A simplified model used categories instead of the continuous predictors in the logistic regression original model. It was anticipated that the performance of this model would only be slightly worse than the original model, while the application in clinical practice would be facilitated. The categorised predictors as shown in Table III were analysed simultaneously with residual mass size. All five predictors had similar odds ratios (Table III: range 2.2-2.8). Therefore, a 'simple score' was constructed by counting the number of favourable characteristics.
Next, we used the two models (Table II and III) to derive alternative resection strategies. These alternative strategies use a cut-off value for the probability of necrosis. If the predicted probability of necrosis is lower than the cut-off value, resection is performed; if not, conservative treatment will follow. The choice of the cut-off values was based on the observed probabilities with the current policies, which apply cut-off values implicity. With 60% and 90% as extremes of the probability of necrosis, two areas with a clear treatment advice evolve. If the probability of necrosis is less than 60%, resection should follow; if the probability exceeds 90%, conservative treatment is advised. In between is a grey area, where the decision to resect a residual mass depends on the cut-off value applied (60%, 70%, 80% or 90%). Table IV shows the probability of necrosis according to the simplified logistic regression model. It can, for instance, be read that the probability of necrosis is less than 60% in patients with a residual mass > 50 mm, in patients with a mass that increased during chemotherapy, in patients with a low score Table V shows the results of the evaluation of the current policies, the alternative policies, and the extreme policy of resection in all patients. The true-positive (TP) rate of the current policies (except policy 2) exceeds 90%. This means that over 90% of the patients with residual tumour would be resected with these policies and that less than 10% of the masses with tumour would be missed. The false-positive (FP) rate varies between 37% and 87%, which means that a large proportion of the patients with necrosis would undergo resection unnecessarily. Policy 2 is remarkable, as both the TP and FP rate are relatively low (74% and 37%). For the alternative policies (7 and 8), it is clear that an increase of the cut-off values for the probability of necrosis, leads to a larger fraction of resected patients and to higher TP and FP rates. Thus, the higher the required probability of necrosis for conservative treatment, the lower the risk of missing tumour, but the higher the risk of unnecessary resection. The diagnostic performance of the policies was further compared by the areas under the ROC curve. The performance of policies 1, 2, 3, 4 and 6 was more or less similar (area 0.72, 0.74, 0.75, 0.69 and 0.75). Policy 5 had a better diagnostic ability (area 0.84), similar to the alternative resection policies (7 and 8). For the alternative policies, cut-off values for the probability of necrosis could be found where these policies dominated over the current policies except policy 5. For example, a cut-off value of 70% with policy 7 resulted in a higher TP rate and a lower FP rate than policy 1 (P<0.001). Similar comparisons were made between the alternative policies and the current policies 2, 3, 4 and 6, which were statistically significant (P<0.05). A cut-off value of 90% leads to a similar performance as policy 5.
The misclassification error shown in Table V indicates that the optimal cut-off value for the probability of necrosis in policy 7 and 8 increases with the relative weight of missing tumour. For example if two, four or eight unnecessary resections are judged to be worth one case of tumour, optimal cut-off values are 70%, 80% and 90% respectively. If the ratio is increased to 16: 1 or higher, resection in all patients (policy 9) is the optimal strategy, since this strategy then has the lowest misclassification error among the policies.
Evaluation of the policies in the 127 largely unselected patients confirms that verification bias is present in the trueand false-positive rates (Table VI) . As expected, the true-and false-positive rates are lower than when evaluated on the total data set for most policies. The areas under the ROC curve are, however, similar to the initial estimates. Also, the alternative policies 7 and 8 still dominate over the other policies (higher TP and lower FP), except policy 5. Therefore, verification bias does not influence our main findings substantially.
Discussion
In this study we evaluated several selection policies for surgery in patients who were successfully treated for metastatic testicular cancer, as apparent from normal tumour markers after chemotherapy. In 45% of these patients, resection was unnecessary, since only totally benign tissue was present. We found that currently recommended policies would lead to resection in between 37% and 87% of these patients. This variation is explained by the patient characteristics considered for selection and the varying degree of certainty that tumour is not missed. Alternative strategies were developed that combine more characteristics than most current policies and hence, have a better inherent diagnostic ability (area under the ROC curve), Moreover, the degree of certainty that tumour is not missed can be decided on by weighing the relative importance of missing tumour against unnecessary resection.
Currently used resection policies are mainly based on a single characteristic, i.e. the size of the residual mass. The policy to resect CT scan-detected masses of 10 mm or larger is probably the most frequently used nowadays. Some strategies include additional characteristics for the selection of patients. Indeed, our previous analyses (Steyerberg et al., 1994 (Steyerberg et al., , 1995 al., 1990) . This is explained by the finding that a large shrinkage is a predictor of necrosis (multivariate P-value = 0.003), rather than a predictor of tumour. The most stringent currently applied selection policy (number 5) (Fossi et al., 1992) , resulted in a combination of the FP and TP rate similar to the use of a high cut-off for the probability of necrosis in the alternative policies (>90%). The similar diagnostic ability is explained by the fact that the three predictors used in this policy, in addition to mass size (primary tumour teratoma-negative, prechemotherapy AFP and HCG normal), were also used in the alternative strategies. At lower cut-off values, these alternative strategies aFor each policy, the table shows the true-positive (TP) rate, the false-positive (FP) rate, the area under the ROC curve (AUC), the percentage of patients undergoing resection, and the classification error for varying weights (non-resection of tumour: resection of necrosis) of misclassification.
Evaluation of resection policies EW Steyerberg et a! m 1497 had better TP and FP rates than the other current policies. For example, the policy to resect masses > 10 mm is dominated by using Table II or Table IV with a cut-off value of 70% for the predicted probability of necrosis.
Although the alternative selection strategies have better diagnostic properties than most current policies, a dilemma remains on the optimal cut-off value for the probability of necrosis. This cut-off value is determined by the relative importance of missing tumour and unnecessary resection. The disadvantages of unnecessary resection include shortterm and long-term morbidity [especially retrograde or anejaculation (Hendry et al., 1993; Nijman et al., 1987) ], mortality and financial costs. Resection of residual mature teratoma or undifferentiated cancer prevents that the mass may grow, and probably decreases the risk of relapse (Toner et al., 1990; Logothetis et al., 1992) . The latter benefits of resection cannot readily be quantified but may be limited for small residual masses (<20 mm), since resection may well be feasible after follow-up of some months. If missing residual tumour is judged at least 4 times as important as an unnecessary resection, the optimal cut-off value is at least 80% for the probability of necrosis. If frequent follow-up is difficult , the risk of missing tumour may be worth 8 or even 16 unnecessary resections, which leads to more aggressive selection with a cut-off value of 90% or resection in all patients as the preferred strategy.
Another consideration is the relative importance of missing mature teratoma or undifferentiated cancer. If the risks of mature teratoma in a small residual mass are considered to be limited, decision-making on resection is dominated by the probability of residual cancer. This probability can be estimated with the formulas in the Appendix (Steyerberg et al., 1995) . If the probability of cancer exceeds, for example, 5%, resection may be indicated, although this implies a value judgment for resection of cancer relative to teratoma and necrosis.
Two limitations of this study have to be considered. First, only operated patients were included and these patients were selected with different criteria in the six participating centres, Evaluation on a subsample with virtually absent selection showed that this verification bias had resulted in overestimated true-and false-positive rates. The areas under the ROC curve were, however, largely unaffected, resulting in the same ordering of the diagnostic performance of the policies. Second, the alternative resection policies have not yet been validated on a new, independent data set. Although several less rigorous validation procedures showed only minor overoptimism of model performance, further conformation is required. We are currently working on such a validation study, which shows promising initial results.
We conclude that a policy that takes into account all currently known predictors may result in improved selection of patients for resection. This means that the balance between the number of beneficial and unnecessary resections will be favourably influenced by the clinical application of such a policy.
